Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + paclitaxel-albumin + oxaliplatin + fluorouracil
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination therapy regimen consists of the PD-1 inhibitor sintilimab and a modified FLOT (mFLOT) chemotherapy backbone, specifically replacing docetaxel with nab-paclitaxel (paclitaxel-albumin), alongside oxaliplatin and fluorouracil (5-FU). Sintilimab is a fully human IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with ligands PD-L1 and PD-L2 to restore T-cell mediated anti-tumor immunity. The chemotherapy components provide synergistic cytotoxic effects: nab-paclitaxel stabilizes microtubules, oxaliplatin induces DNA cross-linking, and fluorouracil inhibits thymidylate synthase. This specific regimen, often referred to as Nab-POF when combined with sintilimab, is being investigated in Phase II clinical trials led by Fudan University for the treatment of advanced or metastatic gastric and gastroesophageal junction cancers, including both HER2-negative and HER2-positive cohorts.
- Other names
- sintilimab plus modified FLOTsintilimab plus mFLOTsintilimab + nab-paclitaxel + oxaliplatin + 5-FU
02
Targets
gp60 (GP60 Receptor)DNAPDCD1 (Programmed cell death protein 1 receptor)SPARC (Secreted protein acidic and rich in cysteine)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sintilimab + paclitaxel-albumin + oxaliplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + paclitaxel-albumin + oxaliplatin + fluorouracil.